This inventor holds 1 USPTO granted patent. Top assignees: St. Jude Children's Research Hospital, University of Massachusetts. Active years: 2000.
Company Filing History:
1 out of 281 
1 out of 1,625 
Years Active: 2000
Title: Scott Hiebert: Innovator in Nuclear Matrix Targeting Peptides
Introduction
Scott Hiebert is a notable inventor based in Brentwood, NJ (US). He has made significant contributions to the field of molecular biology, particularly in the development of nuclear matrix targeting peptides. His innovative work has the potential to enhance therapeutic and diagnostic applications in medicine.
Latest Patents
Scott Hiebert holds a patent for an "Isolated Nuclear Matrix Targeting Peptide." This patent describes nuclear matrix targeting peptides (NMTPs) that are capable of delivering a variety of therapeutic and diagnostic agents, such as transcription regulatory factors, to the nuclear matrix of a cell. This advancement could lead to improved methods for targeting specific cellular components for treatment.
Career Highlights
Throughout his career, Scott Hiebert has worked with prestigious institutions, including the University of Massachusetts and St. Jude Children's Research Hospital. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Scott has collaborated with notable colleagues, including Andre J Van Wijnen and Jeanne B Lawrence. These partnerships have furthered his research and innovation in the area of nuclear matrix targeting.
Conclusion
Scott Hiebert's work in developing nuclear matrix targeting peptides represents a significant advancement in the field of molecular biology. His contributions have the potential to impact therapeutic and diagnostic strategies in medicine.